Navigation Links
Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
Date:9/16/2009

CHENGDU, China, Sept. 16 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE AMEX: TPI), a manufacturer and supplier of modernized traditional Chinese medicines ("TCM") today announced that its new production facility obtained the Good Manufacturing Practices Certificate for pharmaceutical products ("GMP Certificate") from the State Food and Drug Administration ("SFDA") in China.

According to the National Medicine Administration Law of the People's Republic of China, all new pharmaceutical manufacturing facilities must pass an examination to obtain their GMP Certificates. In June 2009, the examination committee visited Tianyin Pharmaceuticals and conducted a review of management practices of its new production facility, including quality control of raw materials, manufacturing processes, and the inspection and acceptance of its finished products. Tianyin's new production facility for solid dosage drugs met all GMP standards.

"We are very pleased with the SFDA's decision to grant us the GMP certification, which is the result of hard work and dedication from our entire team," Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. "This certification is the final step to commencing production at our new facility and effectively tripling the capacity of our solid dosage medicines, such as Azithromycin Dispersible Tablets, Mycophenolate Mofetil Capsules, Dantong Capsules and other recently approved medicines in our portfolio. This will enable us to meet our projected 40% revenue growth for fiscal 2010 while providing the capacity to accommodate up to $100 million in annual revenues as we look toward the future."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 40 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO China
     Tel:   +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:
     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155
     Email: matt.hayden@hcinternational.net

'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
2. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
3. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
4. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
5. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
6. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
7. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
8. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
9. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
10. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
11. Tianyin Pharmaceutical Appoints Three New Independent Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
(Date:2/11/2016)... ... , ... Global Stem Cells Group, a world ... Cells Network (GSCN) to distribute exosome injection and other biological products to stem ... Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, Paraguay, Puerto ...
(Date:2/10/2016)... Inc. (NYSE: BIOA ), a leader in renewable ... Ltd., its partner in the Sarnia ... CDN$25 million in the joint venture for 10% of ...  Mitsui will also play a stronger role in the ... , providing dedicated resources alongside BioAmber,s commercial team. ...
(Date:2/10/2016)... , Feb. 10, 2016  The Maryland House of ... has announced that University of Maryland School of Medicine ... and University of Maryland Medical System President and CEO ... "Speaker,s Medallion," the highest honor given to the public ... Dean Reece and Mr. Chrencik for ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... 2, 2016 Technology Enhancements Accelerate Growth of X-ray ... the digital and computed radiography markets in ... Indonesia (TIM). It provides an ... as well as regional market drivers and restraints. The ... penetration and market attractiveness, both for digital and computed ...
(Date:2/1/2016)... -- Rising sales of consumer electronics coupled ... gesture control market size through ... electronics coupled with new technological advancements to drive global ... through 2020   --> Rising ... to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):